Background: The treatment of chronic granulomatous fungal sinusitis (CGFS), a rare form of invasive fungal sinusitis, is controversial.
Introduction
Chronic granulomatous fungal sinusitis (CGFS) is a unique, chronic form of invasive fungal sinusitis seen in immunocompetent patients, typically from Sudan, India, Pakistan and Saudi Arabia.
The disease, which runs an indolent course, chiefly involves the maxillary and ethmoid sinuses, nose, orbit and cheek (1, 2) . The distinctive presence of non-caseating granuloma containing fungal hyphae differentiates this disease from chronic invasive fungal sinusitis, a disease more commonly seen in Western populations. The diagnostic features of each of these 2 types of chronic fungal sinusitis (1) are listed in Table 1 . Rarely, CGFS may coexist with other types of fungal sinusitis, particularly allergic fungal sinusitis (3) . CGFS is most often caused by Aspergillus flavus and hence variably referred to as invasive rhinoorbital or rhinocerebral aspergillosis (1) .
The selection of an appropriate antifungal drug for treatment of invasive fungal sinusitis is largely based on clinical reports of patient's response to therapy rather than on antifungal susceptibility testing, which has limited reliability at present (4) . shown to be effective in treating CGFS, often in combination with amphotericin B (5) (6) (7) (8) . While in some cases the drug was administered in a planned manner before or after a course of amphotericin B (5, 8) , in other cases, the drug was given when the patient became intolerant to amphotericin B (7) or showed persistent disease (6) . Voriconazole is a triazole drug, which has shown great efficacy in patients with invasive aspergillosis (9, 10) . The drug is well absorbed orally and has few side-effects, making it a very attractive alternative to amphotericin B. Currently, it is recommended as a first line drug for treatment of invasive aspergillosis by the Infectious Disease Society of America (11) .
In the present study, we aimed to review the outcome following therapy with different kinds of antifungals in a series of patients with CGFS to develop an effective protocol for antifungal therapy for future use in such patients.
Materials and methods
We reviewed the clinical records of patients admitted with a diagnosis of CGFS in the ENT department of our hospital between 
Statistical analysis
Descriptive statistics and frequency and percentages were reported for categorical variables. Fisher's exact test (2 tailed) was done to compare outcomes following first line therapy and to compare outcomes in relation to preoperative staging of the disease.
Institutional Review Board approval
Approval of the Institutional Review Board and Ethics committee, Christian Medical College, Vellore, was obtained for the performance of this study (IRB no. 8971).
Results

Demography
The study included 14 males and 4 females whose ages ranged from 20 to 65 years (mean = 46.4 years). 
Symptoms
The duration of symptoms varied from 1 month to 7 years with a mean of 22.9 months. The most common presenting symptoms were visual deterioration (44.4%), proptosis (38.9%), facial pain (38.9%), headache (33.3%) and nasal obstruction (33.3%). The disease was unilateral in all except 3 patients in whom the disease started as a unilateral lesion that progressed to become bilateral. Of 8 patients (44.4%) who had visual deterioration, 3
had total loss of vision in one eye.
Signs
Six (33.3%) patients had periorbital swelling and 5 (27.8%) had ipsilateral cheek swelling. On rigid nasal endoscopic examination, only 4 patients had an obvious nasal mass which was amenable to biopsy. Three (16.7%) patients had sinonasal polyposis.
Prior surgery
Nine (50%) patients had undergone at least 1 surgical procedure involving the sinuses prior to presentation. These included endoscopic sinus surgery in 7 patients, Caldwell Luc surgery in 2 patients, lateral rhinotomy and excision sinonasal mass in one and dental extraction followed by transalveolar biopsy and curettage in another.
Comorbidities
Six (33.3%) patients had diabetes mellitus and 4 (22.2%) were hypertensive. One patient had chronic renal failure.
Fungal smear and culture results
A. flavus was identified in 16 (88.9%) patients. Three patients Fungal culture was negative in 1 patient.
Radiological findings
Based on the radiological extent, patients were categorized into 3 groups (Table 2) 
Histopathology results
All patients had features of CGFS. Typically, the tissue showed a chronic infiltrate of lymphocytes, plasma cells, histiocytes and
Langhans type multinucleate giant cells with epithelioid granuloma with or without necrosis. Fungal hyphae were invariably seen invading tissue or bone. Angioinvasion was not seen in any specimen.
Four of the patients in this series were diagnosed as having mixed fungal sinusitis with a combination of CGFS and allergic fungal sinusitis. These cases have been reported before (3) . All these patients had predominant features of CGFS and areas with allergic fungal sinusitis.
Surgical procedures
Most patients (82.4%) underwent endoscopic excision of the si- Antifungal agents (Table 3) 1. Amphotericin B
Intravenous amphotericin B was commenced as first line of therapy after surgery in 6 patients (38.9%), 3 of whom had stage 2 disease and 3 of whom had stage 3 disease. Plain amphotericin B was administered to 4 patients and liposomal amphotericin B to another 2 patients. Three patients (50%) were intolerant to amphotericin B, one even with liposomal amphotericin B. These patients discontinued the drug without taking the full dose and 
Follow-up (Table 3)
Overall follow-up ranged from 6 months to 8 years with a mean of 2.6 years. Of a total of 18 patients, one patient who died from intercurrent illness was excluded from the analysis. 
I First line Single agent therapy
Amphotericin B
For several years, the gold standard of therapy for all types of invasive fungal sinusitis in both immunocompromised and immunocompetent patients has been amphotericin B. The optimal dose of intravenous amphotericin B is controversial. A dose of 3-5 gm is ideal but few patients are able to tolerate such high doses, because of its toxicity. There are frequent reports of stopping the drug within a few days of commencement of therapy (8, 12) . In the present series, 4 patients had to discontinue the drug because of toxicity. The efficacy of amphotericin B against aspergillus is variable (13, 14) . In our series only one of the 6 patients who received amphotericin B alone had no residual disease on follow-up. This patient had also received oral itraconazole concurrently. Table 3 . Response to first line therapy in relation to type of drug used and stage of disease (n = 18). 1  2  3  1  2  3  1  2  3  1  2  3 Residual disease (n = 5) 3 2
Drugs given as first line therapy
No evidence of disease (n = 13) 1 3 4 1* 1 1 2 *1 patient died after 4 months of therapy due to unrelated causes
Itraconazole
Itraconazole is an azole derivative, which selectively inhibits fungal cytochrome P450 enzymes and reduces the synthesis of ergosterol, a component of the fungal cell membrane. The drug is well absorbed orally after a meal but has poor CSF penetration. The exact dose and duration of itraconazole therapy is poorly defined. Gumaa et al. (15) described good response to oral itraconazole at a dose of 100mg twice daily for 12-19 months in 22 patients. Higher doses of 200mg twice daily have also been recommended. Reports of good response to itraconazole, with or without amphotericin B, have been described by others too (8) . Seven of the 8 patients in our series who had received itraconazole alone with long-term follow-up also showed a good response.
Voriconazole
The sole randomized, controlled trial of voriconazole (given at a dose of 6mg/Kg IV twice daily for 1 day followed by 4mg/ Kg twice daily) versus plain amphotericin B (given at a dose of 1-1.5mg/Kg/Day) in 277 immunocompromised patients with aspergillosis showed greater antifungal efficacy and improved survival at 12 weeks for voriconazole (9) . Based on this study, the The optimal duration of therapy of oral antifungals is controversial, with reports ranging from 6 to 18 months (5, 10) . The risk of recurrence necessitates prolonged treatment. In the present series, most patients with advanced disease received oral voriconazole for at least 9 months to 1 year with minimal side effects. Transient rise in liver enzymes not requiring stoppage of therapy, was seen in 2 patients.
II. First line combination therapy: amphotericin B with itraconazole
Simultaneous therapy
In a series of 21 patients with invasive aspergillosis, half of whom were given a combination of amphotericin B and itraconazole (16) , the authors found that the response to combination therapy was much better (82%) than single drug therapy with amphotericin B alone (50%). No patient was given itraconazole alone in this series. Combination therapy was also found to be useful by other authors (5, 7) .
In the present series, we had only one patient with stage 
Sequential therapy
In a report of 11 patients with craniocerebral aspergillosis who were treated with sequential intravenous amphotericin B and itraconazole (8) , 5 patients failed to receive the full dose of amphotericin B because they developed intolerance to the drug.
These patients received a prolonged course of itraconazole (for 8 to 12 months or longer) and showed a good response, suggesting that itraconazole seemed to have effected the cure. Similar findings were noted by others (12) .
Salvage therapy
Azoles have been used as salvage rather than as first line therapy in many reports (6, 7) . The advantage of azoles is that they can be given orally and have few side-effects. Hence, they are often used for long-term therapy to prevent recurrence. 
IV No medical therapy
Isolated reports of cases of CGFS who have responded to excisive surgery without antifungal therapy exist in the literature (6, 17) . In one report, all 5 patients who did not receive postoperative antifungal therapy showed relapse of disease (14) . None of our patients had resolution of disease with surgery alone and our view is that administration of systemic antifungal therapy is essential for invasive fungal disease.
Our experience
Our experience has been that patients with 
